Status:

TERMINATED

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Lead Sponsor:

AbbVie

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE1

Brief Summary

Metastatic Pancreatic Cancer Disease is one of the most aggressive and deadliest forms of cancer with very poor survival. This study will evaluate adverse events and change in disease activity in part...

Detailed Description

Study study was terminated before the Phase 2 portion of the study began.

Eligibility Criteria

Inclusion

  • Body weight \>= 35 kg.
  • Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease.
  • Measurable disease per Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1).
  • Prior history of or clinically stable concurrent malignancy are eligible for enrollment provided the malignancy is clinically insignificant, no treatment is required, and the participant is clinically stable.

Exclusion

  • Participants with locally advanced disease.
  • Participants with neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.
  • Prior radiotherapy, surgery, or systemic anti-cancer therapy for the treatment of metastatic pancreatic adenocarcinoma.
  • Prior radiotherapy, surgery, or systemic anti-cancer therapy in the adjuvant setting, or earlier, within the last 4 months.
  • Prior radiotherapy to any measurable metastatic lesion at any time.
  • Clinically significant third-space fluid accumulation (e.g., ascites or pleural effusion).
  • Known metastases to the central nervous system (CNS).

Key Trial Info

Start Date :

May 28 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 25 2024

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04807972

Start Date

May 28 2021

End Date

March 25 2024

Last Update

January 7 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

UCHSC Anschultz Cancer Pavilion /ID# 227841

Aurora, Colorado, United States, 80045-2517

2

Johns Hopkins Hospital /ID# 226713

Baltimore, Maryland, United States, 21287

3

Univ Hosp Cleveland /ID# 226807

Cleveland, Ohio, United States, 44106

4

Cleveland Clinic Main Campus /ID# 231135

Cleveland, Ohio, United States, 44195

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis | DecenTrialz